Compare RYTM & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | PIPR |
|---|---|---|
| Founded | 2008 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2017 | 2003 |
| Metric | RYTM | PIPR |
|---|---|---|
| Price | $85.69 | $82.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $131.14 | $91.38 |
| AVG Volume (30 Days) | ★ 960.8K | 460.5K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | 28.34 | ★ 54.49 |
| EPS | N/A | ★ 15.82 |
| Revenue | N/A | ★ $1,904,217,000.00 |
| Revenue This Year | $54.90 | $12.30 |
| Revenue Next Year | $86.58 | $13.55 |
| P/E Ratio | ★ N/A | $5.29 |
| Revenue Growth | N/A | ★ 24.33 |
| 52 Week Low | $55.31 | $72.48 |
| 52 Week High | $122.20 | $380.26 |
| Indicator | RYTM | PIPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 16.52 |
| Support Level | $84.39 | $72.48 |
| Resistance Level | $93.51 | $347.70 |
| Average True Range (ATR) | 4.21 | 2.78 |
| MACD | 0.73 | 2.18 |
| Stochastic Oscillator | 68.33 | 87.69 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.